PDB Short entry for 1VYW HEADER TRANSFERASE 07-MAY-04 1VYW TITLE STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: P33 PROTEIN KINASE; COMPND 5 EC: 2.7.1.37; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: CYCLIN A2; COMPND 9 CHAIN: B, D; COMPND 10 FRAGMENT: C-TERMINAL PORTION, RESIDUES 174-432; COMPND 11 SYNONYM: CYCLIN A; COMPND 12 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 7 EXPRESSION_SYSTEM_CELL_LINE: HIGH FIVE; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 15 EXPRESSION_SYSTEM_PLASMID: PGEX6P KEYWDS TRANSFERASE-COMPLEX, PROTEIN KINASE-COMPLEX, PROTEIN KINASE, KEYWDS 2 TRANSFERASE, SERINE/THREONINE-PROTEIN KINASE, PHOSPHORYLATION, CELL KEYWDS 3 DIVISION, CYCLIN EXPDTA X-RAY DIFFRACTION AUTHOR P.PEVARELLO,M.G.BRASCA,R.AMICI,P.ORSINI,G.TRAQUANDI,L.CORTI,C.PIUTTI, AUTHOR 2 P.SANSONNA,M.VILLA,B.S.PIERCE,M.PULICI,P.GIORDANO,K.MARTINA, AUTHOR 3 E.L.FRITZEN,R.A.NUGENT,E.CASALE,A.CAMERON,M.CIOMEI,F.ROLETTO, AUTHOR 4 A.ISACCHI,G.FOGLIATTO,E.PESENTI,W.PASTORI,A.MARSIGLIO,K.L.LEACH, AUTHOR 5 P.M.CLARE,F.FIORENTINI,M.VARASI,A.VULPETTI,M.A.WARPEHOSKI REVDAT 4 03-APR-19 1VYW 1 SOURCE REVDAT 3 16-JUN-09 1VYW 1 REMARK REVDAT 2 24-FEB-09 1VYW 1 VERSN REVDAT 1 10-JUN-04 1VYW 0 JRNL AUTH P.PEVARELLO,M.G.BRASCA,R.AMICI,P.ORSINI,G.TRAQUANDI,L.CORTI, JRNL AUTH 2 C.PIUTTI,P.SANSONNA,M.VILLA,B.S.PIERCE,M.PULICI,P.GIORDANO, JRNL AUTH 3 K.MARTINA,E.L.FRITZEN,R.A.NUGENT,E.CASALE,A.CAMERON, JRNL AUTH 4 M.CIOMEI,F.ROLETTO,A.ISACCHI,G.FOGLIATTO,E.PESENTI, JRNL AUTH 5 W.PASTORI,A.MARSIGLIO,K.L.LEACH,P.M.CLARE,F.FIORENTINI, JRNL AUTH 6 M.VARASI,A.VULPETTI,M.A.WARPEHOSKI JRNL TITL 3-AMINOPYRAZOLE INHIBITORS OF CDK2/CYCLIN A AS ANTITUMOR JRNL TITL 2 AGENTS. PART 1. LEAD FINDING JRNL REF J.MED.CHEM. V. 47 3367 2004 JRNL REFN ISSN 0022-2623 JRNL PMID 15189033 JRNL DOI 10.1021/JM031145U REMARK 2 REMARK 2 RESOLUTION. 2.30 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2002 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.30 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.86 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.0 REMARK 3 NUMBER OF REFLECTIONS : 94195 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.229 REMARK 3 R VALUE (WORKING SET) : 0.229 REMARK 3 FREE R VALUE : 0.258 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 2.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1908 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.006 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.30 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.44 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 96.50 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 14771 REMARK 3 BIN R VALUE (WORKING SET) : 0.3030 REMARK 3 BIN FREE R VALUE : 0.3280 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 2.00 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 308 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.019 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 8978 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 54 REMARK 3 SOLVENT ATOMS : 410 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 36.50 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 47.60 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 5.48000 REMARK 3 B22 (A**2) : 5.48000 REMARK 3 B33 (A**2) : -10.96000 REMARK 3 B12 (A**2) : 9.08000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.32 REMARK 3 ESD FROM SIGMAA (A) : 0.33 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.36 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.34 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 BOND ANGLES (DEGREES) : 1.200 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 20.80 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.820 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.34 REMARK 3 BSOL : 39.48 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN REMARK 3 PARAMETER FILE 2 : ION.PAR REMARK 3 PARAMETER FILE 3 : WATER_R REMARK 3 PARAMETER FILE 4 : PNU-292137.PAR REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN REMARK 3 TOPOLOGY FILE 2 : ION.TOP REMARK 3 TOPOLOGY FILE 3 : WATER.T REMARK 3 TOPOLOGY FILE 4 : PNU-292137.TOP REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: BULK SOLVENT MODEL USED. THERE IS A REMARK 3 FEATURE IN THE ELECTRON DENSITY MAP ATTACHED TO ASP 28 OF BOTH REMARK 3 CDK2 MOLECULES THAT COULD NOT BE ASSIGNED TO ANY MOLECULE IN THE REMARK 3 CRYSTALLISATION MIXTURE. THIS HAS BEEN MODELLED BY WATER REMARK 3 MOLECULES. REMARK 4 REMARK 4 1VYW COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 07-MAY-04. REMARK 100 THE DEPOSITION ID IS D_1290015178. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 20-NOV-03 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.934 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 94577 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.300 REMARK 200 RESOLUTION RANGE LOW (A) : 35.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 200 DATA REDUNDANCY : 4.800 REMARK 200 R MERGE (I) : 0.08100 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 16.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.30 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.38 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.0 REMARK 200 DATA REDUNDANCY IN SHELL : 4.20 REMARK 200 R MERGE FOR SHELL (I) : 0.69000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.300 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: CNX REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 64.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 4.00 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20% AMMONIUM SULPHATE, 1M KCL, 40MM REMARK 280 HEPES PH 7, PH 7.00 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 62 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 -X,-Y,Z REMARK 290 5555 Y,-X+Y,Z+2/3 REMARK 290 6555 X-Y,X,Z+1/3 REMARK 290 7555 Y,X,-Z+2/3 REMARK 290 8555 X-Y,-Y,-Z REMARK 290 9555 -X,-X+Y,-Z+1/3 REMARK 290 10555 -Y,-X,-Z+2/3 REMARK 290 11555 -X+Y,Y,-Z REMARK 290 12555 X,X-Y,-Z+1/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 143.14667 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 71.57333 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 143.14667 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 71.57333 REMARK 290 SMTRY1 7 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 7 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 143.14667 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 9 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 9 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 9 0.000000 0.000000 -1.000000 71.57333 REMARK 290 SMTRY1 10 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 10 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 10 0.000000 0.000000 -1.000000 143.14667 REMARK 290 SMTRY1 11 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 11 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 11 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 12 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 12 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 12 0.000000 0.000000 -1.000000 71.57333 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3880 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23680 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -20.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3890 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23570 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -21.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 CDK KINASE IS PROBABLY INVOLVED IN THE CONTROL OF THE CELL CYCLE. REMARK 400 INTERACTS WITH CYCLINS A, D, OR E. ACTIVITY OF CDK2 IS MAXIMAL REMARK 400 DURING S PHASE AND G2. REMARK 400 REMARK 400 CYCLIN A2 IS ESSENTIAL FOR THE CONTROL OF THE CELL CYCLE AT THE REMARK 400 G1/S (START) AND THE G2/M (MITOSIS) TRANSITIONS. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -4 REMARK 465 GLU A 299 REMARK 465 ARG A 300 REMARK 465 PRO A 301 REMARK 465 HIS A 302 REMARK 465 ARG A 303 REMARK 465 ASP A 304 REMARK 465 GLY B 168 REMARK 465 PRO B 169 REMARK 465 LEU B 170 REMARK 465 GLY B 171 REMARK 465 SER B 172 REMARK 465 ASN B 173 REMARK 465 GLU B 174 REMARK 465 GLY C -4 REMARK 465 PRO C -3 REMARK 465 LEU C -2 REMARK 465 VAL C -1 REMARK 465 GLU C 299 REMARK 465 ARG C 300 REMARK 465 PRO C 301 REMARK 465 HIS C 302 REMARK 465 ARG C 303 REMARK 465 ASP C 304 REMARK 465 GLY D 168 REMARK 465 PRO D 169 REMARK 465 LEU D 170 REMARK 465 GLY D 171 REMARK 465 SER D 172 REMARK 465 ASN D 173 REMARK 465 GLU D 174 REMARK 465 VAL D 175 REMARK 465 PRO D 176 REMARK 465 ASP D 177 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 12 -144.49 -107.54 REMARK 500 GLU A 40 -18.76 -174.95 REMARK 500 ASP A 127 43.76 -144.35 REMARK 500 ASP A 145 68.01 62.07 REMARK 500 GLU A 162 79.57 -69.00 REMARK 500 VAL A 164 152.46 -49.59 REMARK 500 PRO B 176 179.46 -52.64 REMARK 500 SER B 245 -2.93 -140.37 REMARK 500 PHE B 304 15.53 54.91 REMARK 500 HIS B 321 32.56 -97.13 REMARK 500 ALA B 325 109.44 -45.38 REMARK 500 TRP B 372 108.29 -41.83 REMARK 500 GLU C 8 151.62 178.76 REMARK 500 GLU C 12 -145.78 -143.73 REMARK 500 GLU C 42 -52.82 -132.04 REMARK 500 LEU C 96 -82.83 -57.84 REMARK 500 ARG C 126 -1.97 70.52 REMARK 500 ASP C 127 45.85 -143.51 REMARK 500 ASP C 145 83.81 56.14 REMARK 500 GLU C 162 157.51 -31.39 REMARK 500 VAL C 163 -86.84 -143.65 REMARK 500 TRP C 227 86.57 -150.03 REMARK 500 PRO C 254 5.49 -67.10 REMARK 500 CYS D 193 41.48 -80.12 REMARK 500 PHE D 304 14.32 56.61 REMARK 500 HIS D 321 30.21 -94.64 REMARK 500 TRP D 372 110.87 -36.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1300 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 D 1433 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 292 A 2300 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 292 C 2300 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H06 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2- ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OKU RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ALA- ALA-ABU-ARG-ER-LEU-ILE-(P- REMARK 900 F-PHE)-NH2 REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH REMARK 900 A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5- REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4- REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2- REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1, REMARK 900 4-DIAMINE REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 999 REMARK 999 SEQUENCE REMARK 999 5 AMINO ACIDS EXTRA AT THE N-TERMINUS REMARK 999 RESIDUES 174-432, CHAINS B AND D DBREF 1VYW A -4 0 PDB 1VYW 1VYW -4 0 DBREF 1VYW A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 1VYW A 299 304 PDB 1VYW 1VYW 299 304 DBREF 1VYW B 168 173 PDB 1VYW 1VYW 168 173 DBREF 1VYW B 174 432 UNP P20248 CGA2_HUMAN 174 432 DBREF 1VYW C -4 0 PDB 1VYW 1VYW -4 0 DBREF 1VYW C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 1VYW C 299 304 PDB 1VYW 1VYW 299 304 DBREF 1VYW D 168 173 PDB 1VYW 1VYW 168 173 DBREF 1VYW D 174 432 UNP P20248 CGA2_HUMAN 174 432 SEQRES 1 A 309 GLY PRO LEU VAL ASP MET GLU ASN PHE GLN LYS VAL GLU SEQRES 2 A 309 LYS ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA SEQRES 3 A 309 ARG ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS SEQRES 4 A 309 ILE ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR SEQRES 5 A 309 ALA ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS SEQRES 6 A 309 PRO ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU SEQRES 7 A 309 ASN LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP SEQRES 8 A 309 LEU LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE SEQRES 9 A 309 PRO LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU SEQRES 10 A 309 GLN GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS SEQRES 11 A 309 ARG ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU SEQRES 12 A 309 GLY ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA SEQRES 13 A 309 PHE GLY VAL PRO VAL ARG THR TYR THR HIS GLU VAL VAL SEQRES 14 A 309 THR LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS SEQRES 15 A 309 LYS TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY SEQRES 16 A 309 CYS ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE SEQRES 17 A 309 PRO GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE SEQRES 18 A 309 ARG THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY SEQRES 19 A 309 VAL THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS SEQRES 20 A 309 TRP ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU SEQRES 21 A 309 ASP GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS SEQRES 22 A 309 TYR ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU SEQRES 23 A 309 ALA HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO SEQRES 24 A 309 HIS LEU ARG LEU GLU ARG PRO HIS ARG ASP SEQRES 1 B 265 GLY PRO LEU GLY SER ASN GLU VAL PRO ASP TYR HIS GLU SEQRES 2 B 265 ASP ILE HIS THR TYR LEU ARG GLU MET GLU VAL LYS CYS SEQRES 3 B 265 LYS PRO LYS VAL GLY TYR MET LYS LYS GLN PRO ASP ILE SEQRES 4 B 265 THR ASN SER MET ARG ALA ILE LEU VAL ASP TRP LEU VAL SEQRES 5 B 265 GLU VAL GLY GLU GLU TYR LYS LEU GLN ASN GLU THR LEU SEQRES 6 B 265 HIS LEU ALA VAL ASN TYR ILE ASP ARG PHE LEU SER SER SEQRES 7 B 265 MET SER VAL LEU ARG GLY LYS LEU GLN LEU VAL GLY THR SEQRES 8 B 265 ALA ALA MET LEU LEU ALA SER LYS PHE GLU GLU ILE TYR SEQRES 9 B 265 PRO PRO GLU VAL ALA GLU PHE VAL TYR ILE THR ASP ASP SEQRES 10 B 265 THR TYR THR LYS LYS GLN VAL LEU ARG MET GLU HIS LEU SEQRES 11 B 265 VAL LEU LYS VAL LEU THR PHE ASP LEU ALA ALA PRO THR SEQRES 12 B 265 VAL ASN GLN PHE LEU THR GLN TYR PHE LEU HIS GLN GLN SEQRES 13 B 265 PRO ALA ASN CYS LYS VAL GLU SER LEU ALA MET PHE LEU SEQRES 14 B 265 GLY GLU LEU SER LEU ILE ASP ALA ASP PRO TYR LEU LYS SEQRES 15 B 265 TYR LEU PRO SER VAL ILE ALA GLY ALA ALA PHE HIS LEU SEQRES 16 B 265 ALA LEU TYR THR VAL THR GLY GLN SER TRP PRO GLU SER SEQRES 17 B 265 LEU ILE ARG LYS THR GLY TYR THR LEU GLU SER LEU LYS SEQRES 18 B 265 PRO CYS LEU MET ASP LEU HIS GLN THR TYR LEU LYS ALA SEQRES 19 B 265 PRO GLN HIS ALA GLN GLN SER ILE ARG GLU LYS TYR LYS SEQRES 20 B 265 ASN SER LYS TYR HIS GLY VAL SER LEU LEU ASN PRO PRO SEQRES 21 B 265 GLU THR LEU ASN LEU SEQRES 1 C 309 GLY PRO LEU VAL ASP MET GLU ASN PHE GLN LYS VAL GLU SEQRES 2 C 309 LYS ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA SEQRES 3 C 309 ARG ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS SEQRES 4 C 309 ILE ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR SEQRES 5 C 309 ALA ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS SEQRES 6 C 309 PRO ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU SEQRES 7 C 309 ASN LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP SEQRES 8 C 309 LEU LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE SEQRES 9 C 309 PRO LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU SEQRES 10 C 309 GLN GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS SEQRES 11 C 309 ARG ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU SEQRES 12 C 309 GLY ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA SEQRES 13 C 309 PHE GLY VAL PRO VAL ARG THR TYR THR HIS GLU VAL VAL SEQRES 14 C 309 THR LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS SEQRES 15 C 309 LYS TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY SEQRES 16 C 309 CYS ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE SEQRES 17 C 309 PRO GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE SEQRES 18 C 309 ARG THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY SEQRES 19 C 309 VAL THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS SEQRES 20 C 309 TRP ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU SEQRES 21 C 309 ASP GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS SEQRES 22 C 309 TYR ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU SEQRES 23 C 309 ALA HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO SEQRES 24 C 309 HIS LEU ARG LEU GLU ARG PRO HIS ARG ASP SEQRES 1 D 265 GLY PRO LEU GLY SER ASN GLU VAL PRO ASP TYR HIS GLU SEQRES 2 D 265 ASP ILE HIS THR TYR LEU ARG GLU MET GLU VAL LYS CYS SEQRES 3 D 265 LYS PRO LYS VAL GLY TYR MET LYS LYS GLN PRO ASP ILE SEQRES 4 D 265 THR ASN SER MET ARG ALA ILE LEU VAL ASP TRP LEU VAL SEQRES 5 D 265 GLU VAL GLY GLU GLU TYR LYS LEU GLN ASN GLU THR LEU SEQRES 6 D 265 HIS LEU ALA VAL ASN TYR ILE ASP ARG PHE LEU SER SER SEQRES 7 D 265 MET SER VAL LEU ARG GLY LYS LEU GLN LEU VAL GLY THR SEQRES 8 D 265 ALA ALA MET LEU LEU ALA SER LYS PHE GLU GLU ILE TYR SEQRES 9 D 265 PRO PRO GLU VAL ALA GLU PHE VAL TYR ILE THR ASP ASP SEQRES 10 D 265 THR TYR THR LYS LYS GLN VAL LEU ARG MET GLU HIS LEU SEQRES 11 D 265 VAL LEU LYS VAL LEU THR PHE ASP LEU ALA ALA PRO THR SEQRES 12 D 265 VAL ASN GLN PHE LEU THR GLN TYR PHE LEU HIS GLN GLN SEQRES 13 D 265 PRO ALA ASN CYS LYS VAL GLU SER LEU ALA MET PHE LEU SEQRES 14 D 265 GLY GLU LEU SER LEU ILE ASP ALA ASP PRO TYR LEU LYS SEQRES 15 D 265 TYR LEU PRO SER VAL ILE ALA GLY ALA ALA PHE HIS LEU SEQRES 16 D 265 ALA LEU TYR THR VAL THR GLY GLN SER TRP PRO GLU SER SEQRES 17 D 265 LEU ILE ARG LYS THR GLY TYR THR LEU GLU SER LEU LYS SEQRES 18 D 265 PRO CYS LEU MET ASP LEU HIS GLN THR TYR LEU LYS ALA SEQRES 19 D 265 PRO GLN HIS ALA GLN GLN SER ILE ARG GLU LYS TYR LYS SEQRES 20 D 265 ASN SER LYS TYR HIS GLY VAL SER LEU LEU ASN PRO PRO SEQRES 21 D 265 GLU THR LEU ASN LEU HET SO4 A1300 5 HET 292 A2300 22 HET 292 C2300 22 HET SO4 D1433 5 HETNAM SO4 SULFATE ION HETNAM 292 N-(3-CYCLOPROPYL-1H-PYRAZOL-5-YL)-2-(2-NAPHTHYL) HETNAM 2 292 ACETAMIDE HETSYN 292 PNU-292137 INHIBITOR FORMUL 5 SO4 2(O4 S 2-) FORMUL 6 292 2(C18 H17 N3 O) FORMUL 9 HOH *410(H2 O) HELIX 1 1 PRO A -3 ASN A 3 1 7 HELIX 2 2 PRO A 45 LYS A 56 1 12 HELIX 3 3 LEU A 87 SER A 94 1 8 HELIX 4 4 PRO A 100 HIS A 121 1 22 HELIX 5 5 LYS A 129 GLN A 131 5 3 HELIX 6 6 THR A 165 ARG A 169 5 5 HELIX 7 7 ALA A 170 LEU A 175 1 6 HELIX 8 8 THR A 182 ARG A 199 1 18 HELIX 9 9 SER A 207 GLY A 220 1 14 HELIX 10 10 GLY A 229 MET A 233 5 5 HELIX 11 11 ASP A 247 VAL A 252 1 6 HELIX 12 12 ASP A 256 LEU A 267 1 12 HELIX 13 13 SER A 276 LEU A 281 1 6 HELIX 14 14 ALA A 282 VAL A 289 5 8 HELIX 15 15 TYR B 178 CYS B 193 1 16 HELIX 16 16 GLY B 198 GLN B 203 5 6 HELIX 17 17 THR B 207 TYR B 225 1 19 HELIX 18 18 GLN B 228 LEU B 243 1 16 HELIX 19 19 LEU B 249 GLY B 251 5 3 HELIX 20 20 LYS B 252 GLU B 269 1 18 HELIX 21 21 GLU B 274 ILE B 281 1 8 HELIX 22 22 THR B 287 THR B 303 1 17 HELIX 23 23 THR B 310 LEU B 320 1 11 HELIX 24 24 ASN B 326 SER B 340 1 15 HELIX 25 25 ASP B 343 LEU B 348 1 6 HELIX 26 26 LEU B 351 GLY B 369 1 19 HELIX 27 27 PRO B 373 GLY B 381 1 9 HELIX 28 28 THR B 383 ALA B 401 1 19 HELIX 29 29 PRO B 402 HIS B 404 5 3 HELIX 30 30 GLN B 407 TYR B 413 1 7 HELIX 31 31 LYS B 414 HIS B 419 5 6 HELIX 32 32 GLY B 420 LEU B 424 5 5 HELIX 33 33 ASP C 0 GLU C 2 5 3 HELIX 34 34 PRO C 45 LYS C 56 1 12 HELIX 35 35 LEU C 87 SER C 94 1 8 HELIX 36 36 PRO C 100 HIS C 121 1 22 HELIX 37 37 LYS C 129 GLN C 131 5 3 HELIX 38 38 THR C 165 ARG C 169 5 5 HELIX 39 39 ALA C 170 LEU C 175 1 6 HELIX 40 40 THR C 182 ARG C 199 1 18 HELIX 41 41 SER C 207 GLY C 220 1 14 HELIX 42 42 GLY C 229 MET C 233 5 5 HELIX 43 43 ASP C 247 VAL C 252 1 6 HELIX 44 44 ASP C 256 LEU C 267 1 12 HELIX 45 45 SER C 276 LEU C 281 1 6 HELIX 46 46 ALA C 282 GLN C 287 5 6 HELIX 47 47 TYR D 178 VAL D 191 1 14 HELIX 48 48 GLY D 198 GLN D 203 5 6 HELIX 49 49 THR D 207 TYR D 225 1 19 HELIX 50 50 GLN D 228 MET D 246 1 19 HELIX 51 51 LEU D 249 GLY D 251 5 3 HELIX 52 52 LYS D 252 GLU D 269 1 18 HELIX 53 53 GLU D 274 ILE D 281 1 8 HELIX 54 54 THR D 287 THR D 303 1 17 HELIX 55 55 THR D 310 LEU D 320 1 11 HELIX 56 56 ASN D 326 ASP D 343 1 18 HELIX 57 57 ASP D 343 LEU D 348 1 6 HELIX 58 58 LEU D 351 THR D 368 1 18 HELIX 59 59 PRO D 373 GLY D 381 1 9 HELIX 60 60 THR D 383 ALA D 401 1 19 HELIX 61 61 PRO D 402 HIS D 404 5 3 HELIX 62 62 GLN D 407 TYR D 413 1 7 HELIX 63 63 LYS D 414 HIS D 419 5 6 HELIX 64 64 GLY D 420 LEU D 424 5 5 SHEET 1 AA 5 PHE A 4 GLY A 11 0 SHEET 2 AA 5 VAL A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLY C 11 0 SHEET 2 CA 5 VAL C 17 ASN C 23 -1 O VAL C 18 N ILE C 10 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 CISPEP 1 ASP B 345 PRO B 346 0 0.35 CISPEP 2 ASP D 345 PRO D 346 0 0.53 SITE 1 AC1 3 ASP A 256 GLU A 257 ARG A 260 SITE 1 AC2 5 ARG D 410 LYS D 414 LEU D 423 HOH D2136 SITE 2 AC2 5 HOH D2137 SITE 1 AC3 12 GLU A 8 ILE A 10 ALA A 31 PHE A 80 SITE 2 AC3 12 GLU A 81 PHE A 82 LEU A 83 HIS A 84 SITE 3 AC3 12 GLN A 85 LYS A 89 LEU A 134 HOH A2153 SITE 1 AC4 10 GLU C 8 ILE C 10 ALA C 31 PHE C 80 SITE 2 AC4 10 GLU C 81 PHE C 82 LEU C 83 HIS C 84 SITE 3 AC4 10 LYS C 89 LEU C 134 CRYST1 184.223 184.223 214.720 90.00 90.00 120.00 P 62 2 2 24 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.005428 0.003134 0.000000 0.00000 SCALE2 0.000000 0.006268 0.000000 0.00000 SCALE3 0.000000 0.000000 0.004657 0.00000 MTRIX1 1 -0.235920 -0.878540 0.415330 95.81634 1 MTRIX2 1 -0.871210 0.001880 -0.490910 216.77879 1 MTRIX3 1 0.430500 -0.477660 -0.765840 275.58487 1 MTRIX1 2 -0.259510 -0.858490 0.442330 88.10458 1 MTRIX2 2 -0.864010 0.001770 -0.503480 218.25450 1 MTRIX3 2 0.431450 -0.512830 -0.742200 279.97919 1